Drug delivery systems for intravenous administration
| Technique | Peptide Drug | Outcome | Reference |
|---|---|---|---|
| Peptide drug is linked by a protease-sensitive compound to albumin binding peptide | Glucagon-like peptide 1 (GLP-17-37, 3.4 kDa) | Sustained the pharmacologic effect and prolonged half-life of elimination | Li et al., 2010 |
| Peptide is conjugated using a poly(PEG) methyl ether methacrylate with a comb shape | Salmon calcitonin (3.5 kDa) | Significantly prolonged half-life of elimination (even 15×) but a decrease in potency | Ryan et al., 2009 |
| Adsorption of peptide into porous silicon nanocarriers | Human peptide YY3-36 | Successful delivery of an active peptide but no improvement in circulation time or pharmacokinetic parameters compared with peptide solution | Kovalainen et al., 2013 |
| Immobilization of cysteine including peptide thiolated carboxymethyl dextran-cysteine conjugate | DALCE | Five-fold improvement in elimination half-life and 6.7-fold decreased plasma clearance rate | Shahnaz et al., 2012b |
DALCE, [D-Ala2, Leu5, Cys6]-enkephalin.